Will a Higher Dose of Gantenerumab Aid Patients With Alzheimer’s Disease?

Dr. Scheltens said that prior studies have shown that regions where ARIA-E (ie, imaging abnormalities that are thought to represent parenchymal vasogenic edema or sulcal effusion) occur are where amyloid lowering takes place. The next challenge for researchers is to increase treatment doses until patients have ARIA-E, and then monitor patients without concern about the clinical effects of ARIA, he said.

—Jake Remaly